Century Therapeutics, Inc.
Moat Score — Century Therapeutics, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Century's proprietary Allo-Evasion gene-editing technology and its ability to differentiate a single engineered iPSC line into iNK cells, iT cells, or beta islet cells represent real, patent-protected platform IP. The advantage is bounded by the fact that none of it has yet been validated by an approved product, and rival allogeneic platforms at Fate Therapeutics, Allogene, Caribou, and Nkarta pursue comparably deep immune-evasion engineering. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Century's allogeneic, off-the-shelf model is designed to eventually manufacture cell therapy at lower per-patient cost than autologous CAR-T, which must be custom-made for each patient, and its owned Branchburg, New Jersey facility avoids paying a contract manufacturer's margin. That advantage remains theoretical: Century is still pre-revenue with R&D expense of $95.7 million in 2025 and no commercial-scale manufacturing economics yet proven. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Century has no approved or commercially sold product, so it has no ability to set or defend prices; its only 2025 revenue was a one-time $109.2 million payment tied to Bristol Myers Squibb's termination of their research collaboration, not product sales. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | As a clinical-stage cell therapy developer with no marketed product, Century has no customer base through which a network effect could operate, and its iPSC manufacturing platform creates no value that compounds with the number of patients treated. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no approved therapies on the market, Century has no treating physicians or health systems locked into its products; CNTY-101 remains in an early investigator-sponsored trial, so there is no installed base to create switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Building GMP-grade iPSC manufacturing combined with multi-locus gene-editing capability, as Century has done in Branchburg, New Jersey, requires significant capital and specialized expertise that limits the field to a relatively small set of well-funded players. That barrier is only modestly protective, however, since Fate Therapeutics, Allogene, Caribou, and Nkarta have each built comparable manufacturing and engineering capacity of their own. |